Characterizing 3D neurospheres in healthy and Alzheimer’s models

The allelic composition of an individual's apolipoprotein (ApoE) can significantly impact the risk of developing Alzheimer's disease.

Image Credit: Molecular Devices

Image Credit: Molecular Devices

People with two copies of the E4 allele (ApoE4/4) have a ~65% chance of developing Alzheimer's disease (AD) by age 85, compared to only 10% in people with both wild-type E3 alleles.

This remarkable difference establishes ApoE4 as a significant genetic risk factor for Alzheimer's disease and emphasizes its role in disease pathogenesis.

This app note shows how to replicate Alzheimer's disease in iPSC-derived neurons modified with ApoE allelic variations (E2/2, E3/3, and E4/4).

This biological system of 3D neurospheres and a detailed examination of calcium oscillations offer a potential and informative tool for disease modeling and phenotypic functional evaluation, which can be applied to compound testing.

Download the App Note

About Molecular Devices UK Ltd

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 18, 2026 at 2:16 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Molecular Devices UK Ltd. (2026, June 18). Characterizing 3D neurospheres in healthy and Alzheimer’s models. News-Medical. Retrieved on June 25, 2026 from https://www.news-medical.net/whitepaper/20250604/Characterizing-3D-neurospheres-in-healthy-and-Alzheimere28099s-models.aspx.

  • MLA

    Molecular Devices UK Ltd. "Characterizing 3D neurospheres in healthy and Alzheimer’s models". News-Medical. 25 June 2026. <https://www.news-medical.net/whitepaper/20250604/Characterizing-3D-neurospheres-in-healthy-and-Alzheimere28099s-models.aspx>.

  • Chicago

    Molecular Devices UK Ltd. "Characterizing 3D neurospheres in healthy and Alzheimer’s models". News-Medical. https://www.news-medical.net/whitepaper/20250604/Characterizing-3D-neurospheres-in-healthy-and-Alzheimere28099s-models.aspx. (accessed June 25, 2026).

  • Harvard

    Molecular Devices UK Ltd. 2026. Characterizing 3D neurospheres in healthy and Alzheimer’s models. News-Medical, viewed 25 June 2026, https://www.news-medical.net/whitepaper/20250604/Characterizing-3D-neurospheres-in-healthy-and-Alzheimere28099s-models.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.